HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever Says Findings On Microbiome-Boosting Lipid Technology Will Fuel Product Innovation

Executive Summary

Unilever’s research partnerships are paying off, yielding microbiome findings that are accelerating the firm’s innovation pipeline, with new products envisioned for treating scalp, underarms and oral health in addition to skin, the firm says.

You may also be interested in...



Unilever Goes To Multi-Omics Data With Goal Of Personalizing Acne Intervention

Unilever aims to use Onegevity’s AI and multi-omics database as a platform to develop “new diagnostic models that offer bespoke acne management regiments,” according to the New York-based health intelligence company’s announcement.

E.l.f. Facing Off Against Beauty Giants: Third Among Mass Market Brands As Sales Jump 78%

E.l.f. cosmetics climbed to No. 3 brand in US mass market cosmetics, up two slots from a year ago as it surpassed Revlon and CoverGirl. In its recent sales and earnings presentation, it announced sales in its fiscal 2023 fourth quarter jumped 78%.

Cosmetics Industry’s Preservatives Crisis Grows More Dire Under New Washington State Law

Washington State Governor Jay Inslee signed into law HB 1047 on 15 May, implementing the most aggressive cosmetics ingredient ban in the country. The Personal Care Products Council and Independent Beauty Association are concerned about a lack of alternative preservatives to replace targeted formaldehyde-releasing substances effectively and affordably and the law’s inconsistency with FDA over lead levels, among other impacts.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152729

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel